Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Quidel In-Licenses Flu Antiviral Resistance and Detection Tool

  • Quidel gained exclusive, worldwide rights to the antiviral resistance microarray-based influenza detection technology (AVR-Chip) and the microarray-based influenza B detection technology (BChip) from the University of Colorado at Boulder (CU-Boulder).

    "Exclusive access to molecular-based technologies for influenza B diagnostics and for detection of antiviral resistance, greatly complements our ongoing progress with our MChip technology for influenza A, which was licensed in December 2006 from CU-Boulder, " states Caren Mason, president and CEO.

    The AVR-Chip can identify mutations that may confer resistance to antiviral reagents and may then facilitate proper influenza treatment decisions. The BChip can detect influenza B virus strains. In a study of 62 influenza B virus samples from 19 countries, dating from 1945 to 2005, as well as five negative control samples, the BChip exhibited 97% sensitivity and 100% specificity with no false positives, according to Quidel.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »